STOCK TITAN

Veraxa Biotech (VRXA) Form 4 Filings

VRXA NASDAQ

Here are the Form 4 insider transactions from Veraxa Biotech AG (VRXA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A Form 4 covers the transactions officers, directors and large holders report, so if you follow VRXA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VRXA filings page.

Rhea-AI Summary

Veraxa Biotech AG - Post de-SPAC (VRXA) director Marc Gruninger reported two direct purchases of Ordinary Shares: 9,133 shares at $1.00 per share on October 28, 2026, and 867 shares at $0.98 per share on October 27, 2026. No Rule 10b5-1 plan is reported for these purchases.

Rhea-AI Summary

Veraxa Biotech AG - Post de-SPAC (VRXA) director Christoph Samuel Ziegler purchased 30,000 ordinary shares on October 20, 2026, at $1.09 per share. His reported direct holdings after the transaction were 37,932 ordinary shares. No Rule 10b5-1 plan is reported.

Rhea-AI Summary

Veraxa Biotech AG (VRXA) director Oliver Rolf Baumann reported an indirect open-market purchase of Veraxa ordinary shares. On 2026-08-27, an entity associated with him, Akira Holding AG, purchased 50,000 Ordinary Shares at $1.50 per share. Following this transaction, Akira Holding AG holds 5,773,618 Veraxa ordinary shares that Baumann may be deemed to beneficially own.

Rhea-AI Summary

Veraxa Biotech AG (VRXA) reported that Chief Executive Officer and director Christoph Rudiger Antz purchased 5,000 Ordinary Shares on 2026-08-27 in a non-derivative, open-market or private transaction at a price of $1.53 per share. Following this transaction, he directly owns 5,000 Ordinary Shares.